Experimental drug for advanced triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests an experimental drug called HLX43, given alone or with other immune-boosting drugs, for people with advanced triple-negative breast cancer (a type of breast cancer that does not have the common hormone receptors). The goal is to see if this drug can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your tumor must be confirmed as triple-negative breast cancer (meaning it is negative for estrogen, progesterone, and HER2 receptors).
- Your cancer must be locally advanced, recurrent, or metastatic — meaning it has spread or come back and cannot be removed with surgery.
- If you have not yet received any systemic treatment for advanced disease, you can join Phase II. If you have had one or more prior lines of standard treatment for recurrent/metastatic disease, you can join Phase I.
- You must have at least one measurable tumor that can be seen on a scan, and it must not be in an area previously treated with radiation unless it has grown since.
- You must be able to provide a tumor tissue sample (from a previous biopsy or surgery) for testing.
- You must have good performance status (ECOG 0-1), meaning you are up and about with little or no help.
- You must have adequate organ function (bone marrow, liver, kidneys).
- You cannot have had certain prior treatments like irinotecan, topotecan, or some ADCs that target Trop-2.
- You cannot have active brain metastases, autoimmune disease, uncontrolled infections, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (HLX43) for people with a certain type of advanced breast cancer that has stopped responding to hormone therapy. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
This trial tests whether adding an immunotherapy drug (HLX10) to chemotherapy before surgery, and then continuing it after surgery, helps people with triple-negative breast cancer more than chemotherapy alone. It is a type of breast cancer that does not respond to hormone treatments or HER2-targeted treatments.
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
This trial tests an experimental drug called QLC5513, either by itself or combined with another drug (QL1706), for people with triple-negative breast cancer that has continued to grow despite prior treatment. The goal is to see if this new approach can shrink tumors or slow the cancer's progression, and it might be an option if standard treatments have stopped working.
This trial tests a new drug, HLX43, that targets a protein called PD-L1 on cancer cells and delivers a chemotherapy-like payload directly to them. It's for people with advanced colorectal cancer that hasn't responded to standard treatments.
This trial tests a new drug called HLX43 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It aims to find safe dosing and understand how the drug works in the body.
Hear when a new Breast Cancer (Triple Negative Breast Cancer (TNBC)) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.